In fact, among the anti-apoptotic proteins that are overexpressed in CLL, levels of the anti-apoptotic MCL1 and BCL-XL proteins are decreased after ibrutinib, while venetoclax selectively antagonizes BCL2 [82,83]. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.